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Abstract
Background: Little is known about the effect of smoking cessation on airway inflammation. Secretory Leukocyte
Protease Inhibitor (SLPI), Clara Cell protein 16 (CC16), elafin and human defensin beta-2 (HBD-2) protect human
airways against inflammation and oxidative stress. In this longitudinal study we aimed to investigate changes in
sputum and nasal lavage SLPI, CC16, elafin and HBD-2 levels in healthy smokers after 6 and 12 months of smoking
cessation.
Methods: Induced sputum and nasal lavage was obtained from healthy current smokers (n = 76) before smoking
cessation, after 6 months of smoking cessation (n = 29), after 1 year of smoking cessation (n = 22) and from 10
healthy never smokers. SLPI, CC16, elafin and HBD-2 levels were measured in sputum and nasal lavage
supernatants by commercially available ELISA kits.
Results: Sputum SLPI and CC-16 levels were increased in healthy smokers before smoking cessation versus never-
smokers (p = 0.005 and p = 0.08 respectively). SLPI and CC16 levels did not differ before and 6 months after
smoking cessation (p = 0.118 and p = 0.543 respectively), neither before and 1 year after smoking cessation (p =
0.363 and p = 0.470 respectively). Nasal lavage SLPI was decreased 12 months after smoking cessation (p = 0.033).
Nasal lavage elafin levels were increased in healthy smokers before smoking cessation versus never-smokers (p =
0.007), but there were no changes 6 months and 1 year after smoking cessation.
Conclusions: Only nasal lavage SLPI decrease after 1 year after smoking cessation. We may speculate that there is
an ongoing inflammatory process stimulating the production of counter-regulating proteins in the airways of
healthy ex-smokers.
Background
Smoking exerts its primary effects on the respiratory
tract, and is associated with the development of several
diseases such as cancer and chronic obstructive lung dis-
ease (COPD) [1]. COPD involves airway inflammation
and a probable protease-antiprotease imbalance. How-
ever, little is known about the underlying mechanisms
and how they are related to the susceptibility to the dis-
ease, particularly why only 10-15% of smokers develop
COPD [2]. Currently, there are no biological markers suf-
ficiently sensitive to assess parenchymal lung health
before functional abnormalities become apparent.
Consequently, lung-specific biomarkers, indicating
epithelial cell activation or damage, produced by distinct
regions of the respiratory tract, are desirable for evaluation
of smoking exposure, effects and identification of suscepti-
ble individuals to smoking. The respiratory epithelium,
according to anatomical location (nose, trachea, bronchi,
distal airways and alveoli), secretes several specific proteins
into the airspaces of the respiratory tract. These include
Secretory Leukocyte Protease Inhibitor (SLPI), the 16-kDa
bronchiolar Clara cell secretory protein (CC16), elafin, as
well as human beta b-defensins-2 (hBD-2).
Secretory Leukocyte Protease Inhibitor (SLPI) and elafin,
two serine protease inhibitors, are produced by a number
of cell types in the respiratory tract. They protect local tis-
sue against the detrimental consequences of inflammation
not only as a result of their anti-inflammatory activities
but also via their antiprotease and antimicrobial properties
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exposure and one of the main secretory proteins in the
lung [5]. CC16 is produced mainly by Clara cells in the
lung and also by non-ciliated cells along the tracheobron-
chial epithelium and similar cell types in the nasal cavity
[6]. It plays an important protective role in the respiratory
tract against oxidative stress and inflammation [7]. HBD-
2, widely expressed in epithelial cells lining the respiratory
tract, is primarily known for its antimicrobial activities [8].
However, it is now clear that it has anti-inflammatory
effects as well [9].
Serum, sputum, Bronchoalveolar Lavage Fluid (BALF),
nasal lavage and bronchial epithelial cell expression of
CC16 is reported to be lower in smokers with normal
lung function in most of the studies [5,10-18]. These
changes seem to be related to pathogenesis of smoke-
related lung diseases. We and others have found a
further decrease in CC16 in COPD and its exacerbations
[11,14,19,20]. However, in one study, healthy smokers
had a relative high level of CC16 in the airways, with
similar levels in bronchial fluids between smokers and
non-smokers [21]. Furthermore, we have found
increased levels of CC16 in sputum and Lindahl et al
found higher levels of CC16 in BALF and nasal lavage
of smokers than nonsmokers, which is in contrast with
other previous reports [6,20].
Currently little is known about the effects of smoking
o nt h eo t h e rb i o m a r k e r s .P r e v i o u s l yw eh a v ef o u n d
increased SLPI in sputum in healthy smokers compared
to never-smokers, which is further increased in COPD
patients, but no difference in elafin and HBD-2 between
the two groups [20]. Former studies have shown that
acute exposure to cigarette smoke in the mouse lung
induces a loss of activity of SLPI [22], while chronic
smoke exposure increased SLPI expression in the
smoke-exposed mice [23]. Moreover, smoke exposure
has been associated with significantly reduced HBD-2
levels in pharyngeal washes and sputum of patients with
acute pneumonia, suggesting increased susceptibility to
infection [24]. This mechanism may be important in the
pathogenesis of COPD, as increased defensin levels are
observed in inflammatory lung diseases [25]. To the best
of our knowledge there are no studies about the effect
of smoking on elafin levels.
It remains uncertain whether expression of these bio-
markers is altered after smoking cessation. There is only
one longitudinal study in BALF, which showed signifi-
cant higher levels of CC16 after smoking cessation,
which failed to remain after 15 months of smoking ces-
sation [26]. No other longitudinal studies have reported
the effect of smoking cessation on SLPI, elafin and
HBD-2 in “healthy” smokers. We have conducted a
longitudinal study to examine whether changes in spu-
tum and nasal lavage SLPI, CC16, elafin and HBD-2 are
reversed after a period of 6 months and 12 months
smoking cessation in “healthy” smokers.
Methods
Subjects
In the University Hospital of Heraklion, Crete induced
sputum and nasal lavage was obtained from 76 smokers,
recruited from the smoking cessation clinic, before their
entrance into the smoking cessation protocol. All sub-
jects provided written informed consent and ethical
approval was provided by the University Hospitals Ethics
Committee. Following enrollment, all smokers partici-
pated in the same behavioural therapy program and
according to their degree of dependence (Fagerstrom
test) they received nicotine replacement therapy and/or
bupropion as part of their smoking cessation treatment.
Ten never-smokers were recruited by advertisement and
were the control subjects. All subjects were free of any
respiratory tract infections at the time of the study or
during the month preceding the study and at the follow-
up at 6 and 12 months. Subjects did not suffer from any
disease and did not receive any medication at the time of
the first visit, and none had symptoms of chronic bron-
chitis. Furthermore, baseline lung functional tests were
within the normal range and their chest radiographs
were normal. During each follow-up, confirmation of
smoking status was assessed by exhaled CO.
The participating subjects’ characteristics are depicted
in Table 1. The studied population participated in a par-
allel study aiming to investigate the levels of the same
biomarkers in COPD and IPF. Results from that study
have been recently published [20].
Sputum induction and processing
Sputum was induced and processed as previously
described [27]. Subjects inhaled hypertonic saline for three
ten-minute sessions. The concentration of the inhaled sal-
ine was consecutively increased in each session from 3%,
to 4% and to 5%. Always between sessions the inhalation
procedure was interrupted and the subjects were asked to
blow their nose, rinse their mouth and try to expectorate
sputum into a sterilized box. By this way saliva contamina-
tion of the sample was minimized and the percentage of
squamous cells in the sample was decreased. Sputum was
processed within the next 30 min or no more than two
hours, with the sample always kept in ice. The volume of
the sputum was measured and sputum samples with a
volume of at least 2 mL are reputed to be sufficient. The
more viscid proportions of the sputum (plugs) were
selected and weighed. Dithiothreitol (Calbiochem, Darm-
stadt, Germany) was added, followed by phosphate buffer
saline (PBS). Then, the mixture was filtered and centri-
fuged. The sol phase was removed and stored at -80°C
until analyzed. The cell pellet was resuspended with PBS,
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lity was tested by means of trypan blue exclusion method.
The sample was considered for further analysis if squa-
mous cell contamination was < 20% and cell viability was
> 50%,. Sputum cytospin slides were stained using May-
Grunwald Giemsa for differential cell count. Cell counting
was performed by one investigator (IB), blind to the origin
of the samples. At least 400 cells were counted. Cytospins
with < 50% squamous cells and > 400 nonsquamous cells
were qualified as of good quality. Cell differential counts
were expressed as % of total sputum non-squamous cells.
Nasal lavage
Briefly, the subjects, in a seated position, were instructed
to flex their neck approximately 30° from the vertical
and to not breathe through their nose. Five milliliters of
normal saline was gently instilled into each nostril using
a syringe with a dwelling time of approximately 10 sec-
onds. The lavage fluid was then collected by repeated
aspiration from both nasal cavities, kept on ice, weighed,
and processed within 1 hour (centrifugation for 10 min-
utes at 400 g and storage of supernatant at -80°C pend-
ing analysis).
Assessment of mediators
Commercially available ELISA kits were used to mea-
sure SLPI (R&D Systems Europe Ltd, Abingdon, UK),
CC16 (Biovendor GmbH, Heidelberg, Germany), elafin
(R&D Systems Europe Ltd, Abingdon, UK), and HBD-2
(EMELCA Bioscience, Breda, The Netherlands), in
accordance with the manufactors instruction. “Recovery”
experiments were performed to determine if the kits’
reagents were suitable for application in nasal lavage
and sputum samples. Samples were split into two ali-
quots and one aliquot was run as “neat or unspiked”,
while the other aliquot was “spiked” with a small
volume of the kit standard concentrate, then compared
to a “spiked” diluent. The spiked sample was also tested
by diluting it to determine if it dilutes parallel to the
standard curve. The recoveries were always in the range
of 80-120%.
Assays were performed in duplicate. The readings of
each standard and sample were averaged and the aver-
age of zerostandard was subtracted The mean intra-
sample CV was < 4%. The detection limits of SLPI,
CC16, elafin and HBD-2 were 62.5 pg/ml, 20 pg/ml,
31.25 pg/ml and 8 pg/ml respectively.
2.3. Statistical Analysis
Normality was tested by the Shapiro-Wilk test. Variables
were non-normally distributed. Only successful quitters
at 6 months (n = 29) and 1 year (n = 22) were included
in the analysis of repeated measurements using the
Friedman test followed by the Wilcoxon Signed Ranks
test to see pair-wise differences. Differences between
smokers and the control group were tested using the
Mann-Whitney U test. The software StatsDirect (SPSS
Statistics 17.0.0 CHICAGO IL, USA) was used. Probabil-
ity values of < 0.05 were considered as statistically
significant.
Results
A total of 76 smokers and 10 controls enrolled in the
study. Successful quitters were 29/76 (38.2%) at 6
months and 22/76 (29%) at 1 year. Good quality sputum
specimens were obtained a) at baseline from 68
“healthy” current smoker subjects (8 subjects declined to
have sputum induction, b) after 6 months of smoking
cessation from 21 of 29 subjects who successfully mana-
ged to quit smoking, c) after 1 year of smoking cessation
from 14 of 22 who had not relapsed, and d) from all 10
controls. Nasal lavage was obtained a) at baseline from
69 “healthy” current smoker subjects (7 subjects
declined to have nasal lavage) b) after 6 months of
smoking cessation from 22 of 29 subjects who success-
fully managed to quit smoking, c) after 1 year of smok-
ing cessation from 12 of 22 who had not relapsed, and
d) from all 10 controls.
Table 1 Subject characteristics
Time Smokers Never-smokers
Before sm-ces 0 After sm-ces 6 m After sm-ces 12 m 0
N 76 29 22 10
Sex, M/F 65/11 26/3 20/2 8/2
Age, (yr) 48 ± 9 48 ± 8 47 ± 7 33 ± 9*
Smoking (p-yr) 57 ± 18 53 ± 16 56 ± 18 N/A
FEV1,%pred 104 ± 11 105 ± 13 108 ± 9 114 ± 14
FEV1/FVC% 80 ± 6 81 ± 5 80 ± 6 87 ± 6
Fagerstrom score 8±2 7±1 7±1 N / A
Data are presented as mean ± SD, or in absolute numbers. sm-ces: smoking cessation, N: numbers, M: male, F: female, yr: years, p-yr: pack years, FEV1: forced
expiratory volume in one second, FVC: forced vital capacity, N/A: non applicable.
* p < 0.05 versus successful quitters at baseline.
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5 nicotine replacement therapy (7%), 26 both agents
(34%) and 5 refused to receive any treatment (7%). The
duration of treatment was median (range), 4 (0-10)
weeks. Of those who successfully quitted smoking at 6
months (n = 29), 19 received bupropion (66%), 1 nico-
tine replacement therapy (3%), 8 both agents (28%) and
1 refused to receive any treatment (3%), while of those
who successfully quitted smoking at 1 year (n = 22), 16
(72%) received bupropion, 1 nicotine replacement ther-
apy (5%) and 5 both agents (23%). The duration of treat-
ment was 5 (0-8) weeks for successful quitters at 6
months and 5 (0-8) weeks for successful quitters at 1
year.
Concentrations of SLPI, CC16, elafin and HBD-2 in
sputum and nasal lavage are shown in Table 2 and
Table 3, respectively. The concentration of SLPI and
elafin was significantly higher in nasal lavage than in the
sputum (p = 0.0001 and p = 0.022, respectively). The
concentration of CC-16 was higher in sputum compared
to nasal lavage (p = 0.001). However, the levels in most
of the nasal lavage samples of HBD-2 were below the
detection limit so we did not report those results.
In sputum, SLPI and CC16 levels were increased in
healthy smokers before smoking cessation versus never-
smokers (p = 0.005 and p = 0.08 respectively). However,
SLPI and CC16 levels did not differ before and 6
months after smoking cessation (p = 0.118 and p =
0.543 respectively), and neither before and 1 year after
smoking cessation (p = 0.363 and p = 0.470 respec-
tively). Furthermore HBD-2 and elafin levels did not dif-
fer in healthy smokers before smoking cessation versus
never-smokers. HBD-2 did not differ before and 6
months and 1 year after smoking cessation. Although
elafin was lower 6 months after smoking cessation (p =
0.025), 12 months after smoking cessation its levels
were the same as those before smoking cessation. More-
over, there was no difference in nasal lavage, SLPI,
CC16 between healthy smokers before smoking cessa-
tion and never-smokers. SLPI was lower 12 months
after smoking cessation (p = 0.033). Nasal lavage elafin
levels were increased in healthy smokers before smoking
cessation versus never-smokers, p = 0.007. However,
there were no changes in nasal lavage elafin and CC16 6
months and 1 year after smoking cessation. We did not
find any correlation in mediator concentrations between
each other.
Discussion
The present study was performed to examine respiratory
fluid obtained from the nose and induced sputum for
lung-specific biomarkers. BALF has been used to assess
airway inflammation in various diseases, but as it is a
difficult invasive method and has several limitations it
can not be used extensively. Sputum induction has been
proposed as a non-invasive method that could give valu-
able information for lung injury, the Th1/Th2 response,
the inflammatory process, and the effects of pharmaco-
logical treatment [28]. Our primary endpoint was to
detect tobacco insults to the respiratory epithelium and
study the signs of possible repair after smoking cessa-
tion. We chose nasal lavage fluid and sputum because
they are easy, non-invasive methods that additionally
contain a large number of proteins, which comprise a
potential source for detecting and characterizing bio-
chemical alterations associated with airway diseases. It
may also be possible to monitor protein changes but
also give information of inflammation processes in the
lower airways [27,29]. Biomarkers of oxidative stress and
airway inflammation including 8-isoprostane [30] and
leukotriene B4 [31] have also been measured in exhaled
breath condensate, a non-invasive method for sampling
airway secretions [32], in healthy smokers and patients
with COPD. Furthermore, electronic nose is a promising
non-invasive technique for assessment of airway inflam-
mation [33].
Table 2 Concentrations of measured variables in sputum
Smokers Controls
(n = 10)
Before
(n = 21)
6 m sm cessation
(n = 21)
12 m sm cessation
(n = 14)
SLPI
(μg/ml)
1.11 (0.3-4.9) 0.8 (0.2-2.6) 1.36 (0.3-3.3) 0.1 (0.05-0.6)*
CC16
(ng/ml)
1700 (300-13000) 1800 (100-21000) 1900 (60-5500) 500 (1-4800)*
b-defensin
(pg/ml)
74.26 (8 - 534,91) 98.1 (10.2 - 729.9) 83.1 (8 - 256) 73.5 (34.6 - 409.9)
Elafin
(pg/ml)
252.9 (92.8 - 2146.7) 171.9 (71.2 - 472.9)* 236.4 (44.6 - 714.1) 194.6 (128.8 - 276.8)
Data are presented as median (range). Sm cessation: smoking cessation.
* p < 0.05 versus successful quitters at baseline
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play an important role in protease-antiprotease balance
and in controlling elastase levels. Additionally, this
investigation could be considered extremely important
in diseases such as COPD and asthma where the cyto-
kine network plays a key role and therefore could poten-
tially be used in the future as therapeutic agents. We
chose SLPI, CC16, elafin and HBD-2 because they are
key proteins that have been found in human airway
secretions indicating respiratory epithelial cell activation
or damage [3-8] for evaluation of smoking exposure and
signs of possible repair after smoking cessation. Regard-
ing the validation of the mediators, our study confirmed
that the assay for the 4 mediators were all reproducible
with each of these assays giving > 80% recovery of a
“spike” with pure reagent.
Our results showed that sputum SLPI, CC16, elafin and
HBD-2 levels do not decrease up to 1 year after smoking
cessation. We can not exclude the possibility that a
decrease could take place the following years [26] as our
study was limited to 12 months. The Clara Cell Secretory
protein after 15 months of smoking cessation declined to
the reduced levels noted before smoking cessation.
Twelve months of smoking cessation decrease signifi-
cantly only nasal lavage SLPI, suggesting that there is an
ongoing inflammatory process stimulating the produc-
tion of counter-regulating proteins in the airways of
healthy ex-smokers. The differences found between spu-
tum and nasal lavage need further investigation as con-
trary to that expected only nasal lavage showed a
decrease in the investigated levels.
Reports on serum, sputum, nasal lavage, BALF and
bronchial epitheliums CC16 levels are controversial,
showing either a decrease [5,10-18], no change [21] or
an increase [6] in smokers with normal lung function
compared to never smokers. These discrepancies could
reflect the difficulty in comparing CC16 in the fluid
phase of respiratory samples, mainly for methodology
reasons. Also it is difficult to compare published studies
in serum with others in sputum and nasal lavage as
firsts are representative of the entire body rather than
only the lung burden. We found higher levels of CC16
in sputum of smokers compared to nonsmokers, which
is in accordance with the study of Lindahl et al [6]. It
seems likely that the increase in CC16 levels observed in
smokers in the present study reflects a regenerative pro-
cess involving the Clara cells. The higher levels could
also explain why these subjects did not develop COPD
as in COPD usually a decrease is observed [14]. Further
longitudinal studies are needed in order to clarify which
are the potential other factors that make some smokers
as in our study to have high levels of CC16 contrary to
the other previous studies and which is exactly the role
of these mediators. Probably an earlier step in the
immune response or other associated factors are respon-
sible of either increase, decrease or no change. Further
investigation is needed and should considered important
as it could in part explain the reasons of why some
smokers develop COPD and some do not. Furthermore
the increase in sputum SLPI and nasal lavage elafin in
smokers might be a part of the local defence against
inflammatory processes to minimize tissue damage
induced by smoking. SLPI and elafin are characterized
as alarm molecules involved in the regulation of early
events in the inflammatory process [34], therefore the
overexpression of these inhibitors would be of benefit in
combating the inflammatory consequences of smoking.
The possible important role of these two anti-inflamma-
tory proteins has also been shown in a recently pub-
lished study of our group where elafin was increased
only in smokers that develop COPD. On the other hand
SLPI is increased in smokers independently of whether
they have developed COPD or not [20]. This has also
been confirmed in our study where smokers with no
lung disease have increased SLPI.
We did not find any changes in sputum HBD-2
between smokers and non-smokers and there are not
enough data in the literature about the effects of smok-
ing on HBD-2, recruiting healthy smokers. Smoking has
been proven to be a factor for bacterial colonisation in
the respiratory tract. Toll-like receptors (TLRs) possess
a key role in host defence in the respiratory tract. The
Table 3 Concentrations of measured variables in nasal lavage fluid
Smokers Controls
(n = 10)
Before
(n = 22)
6 m sm cessation (n = 22) 12 m sm cessation (n = 11)
SLPI (μg/ml) 3.2 (0.1-37.5) 1.96 (0.2-25.8) 1.9 (0.05-13.4)* 2.7 (0.2-7)
CC16 (ng/ml) 26.3 (1.5-200) 34 (0.8-169.4) 38.9 (0.8-80) 25.6 (1.3-200)
b-defensin (pg/ml) -- --
Elafin (pg/ml) 6701.5 (1195.8-17360.5) 5927.8 (339.5-13298.4) 3284 (328.9-7398) 1665.5 (484.9-5894.2)*
Data are presented as median (range). Sm cessation: smoking cessation.
* p < 0.05 versus successful quitters at baseline
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of the innate host defence. In a study that used surgical
specimens from current smoker COPDs, former smoker
COPDs, healthy ex-smoker and smoker subjects the
expression of HBD2 in the epithelium of distal airways
was higher only in current smokers with COPD [35].
MacRedmond et al showed TLR2 expression was
unchanged in the nasal epithelium of smokers compared
with non-smoking controls [36]. There is only one study
in patients with acute pneumonia, reporting reduced
HBD-2 levels in pharyngeal washes and sputum in cur-
rent and former smokers [24].
To the best of our knowledge there is very limited evi-
dence that has studied the alteration of these biomarkers
after smoking cessation. The present study is one of the
first longitudinal studies that investigate the effect of
smoking cessation on SLPI, CC-16, elafin and HBD-2 in
induced sputum and nasal lavage of smokers with no
concurrent disease or lung function impairment.
One previous longitudinal study assessing the effect of
1, 3,6, 9 and 15 months smoking cessation in smokers
with normal lung function, showed significantly (p <
0.05) higher levels of CC-16 in BAL fluid at 3, 6, and 9
months after smoking cessation. However 15 months
after smoking cessation CC-16 levels were the same as
those before smoking cessation [26]. In accordance with
this study we found that sputum and nasal lavage CC-
16.levels do not change up to 1 year of smoking cessa-
tion. This could be explained by an irreversible insult to
the bronchiolar epithelium from tobacco smoke, sug-
gesting that the regenerative process is incomplete.
Another explanation is that more than 12 months of
smoking cessation are needed to observe permanent
changes in lung biomarkers related to cigarette smoking.
Our understanding of the effect of smoking and smok-
ing cessation on HBD-2 and elafin is limited at present
and this should be an area of study in the coming years.
Future studies are required to elucidate their role in the
pathogenesis of inflammatory lung diseases [25].
Limitations-Strengths
Our study has some limitations that deserve comment.
Firstly, our data could be criticised by the fact that 29
and 22 individuals (successful quitters at 6 months and
1 year, respectively) completed the evaluation. However
this is common in smoking cessation clinics where
relapse is frequent. Further we restricted our repeated
analysis only in successful quitters. Moreover, our con-
trol group included only 10 subjects, which did not
match with the number of healthy smokers, similar with
other studies using induced sputum attempt. Although,
there is a concern about the possibility of statistical
error type-II, the comparisons between healthy smokers
and non-smoking control individuals are not susceptible
for this type error, because we have already detected sta-
tistical significance. Statistical type II is possible in the
case of SLPI measurements where we detected a ten-
dency of important but statistically insignificant differ-
ences and larger studies are needed to verify the issue.
Thus the power of the study maybe improved, in the
case of SLPI, only by increasing the number of healthy
smokers, successful quitters, reaching the appropriate
end-study sample size of 170 individuals. Taking into
account that in cessation clinics worldwide only 25-30%
are successful quitters in the first year and that the suc-
cess of sufficient sputum is 80% we need to recruit 800
individuals at baseline to obtain adequate power.
Secondly, nasal lavage samples the nose and sputum
induction samples primarily the lumen of the central
airways. Consequently, sputum and nasal lavage changes
in lung-specific biomarkers do not necessarily reflect
changes in airway wall. However, common methods to
study tissue, such as the examination of bronchial biop-
sies or surgical specimens cannot be easily applied on
longitudinal studies. Thirdly, the mean age of the smo-
kers’ group was greater than that of the control group
and it could be argued that differences between smokers
and never-smokers are due to the age difference.
Although this cannot be excluded, an analysis of sub-
groups of different ages did not show differences (data
not shown). Furthermore, as sputum was treated with
the mucolytic agent dithiothreitol (DTT), a possible
influence of DTT treatment on detection of these solu-
b l em e d i a t o r sh a st ob ec o n s i d e r e d .T h er e d u c i n ga g e n t
DTT could have interfered with the detection of inflam-
matory mediators in the sputum sol phase, either by
affecting the three dimensional structure of proteins
causing the release of mucus bound molecules, or by
interfering directly with the immunoassay. In the pre-
sent study a detailed analysis of the effects of DTT on
these was not performed. However, several studies have
excluded that DTT has an effect on mediators. Wool-
house et al, has investigated the effect of sputum proces-
sing with DTT on detection of inflammatory mediators
and showed that DTT does no significantly affect med-
ian levels of SLPI [37]. Moreover, de Burbure et al
assessed the effect of DTT treatment on the concentra-
tions of CC16 by adding DTT to sputum samples. Con-
centrations of CC16 in treated and untreated samples
were highly correlated with no systematic difference
(post-treatment values averaged 102% of the pre-treat-
ment values) [38].
Conclusions
In conclusion, we have shown that sputum biomarkers
levels do not decrease up to 1 year after smoking cessa-
tion. Twelve months of smoking cessation decrease sig-
nificantly only nasal lavage SLPI, suggesting that there is
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duction of counter-regulating proteins in the airways of
healthy ex-smokers. Further investigations are needed to
explore if these proteins could be valid biomarkers for
monitoring peripheral airway damage.
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